uniQure Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

Wall Street analysts have given uniQure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but uniQure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

uniQure saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 2,220,000 shares, a decrease of 22.1% from the August 15th total of 2,850,000 shares. Based on an average daily volume of 449,100 shares, the days-to-cover ratio is currently 4.9 days. Currently, 6.4% of the shares of the company are short sold.
View uniQure's Short Interest.

uniQure is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for uniQure.

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Sunday, July, 25th. The biotechnology company reported $8.51 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.97 by $5.54. The biotechnology company earned $463.87 million during the quarter, compared to the consensus estimate of $212.65 million. uniQure had a net margin of 60.66% and a trailing twelve-month return on equity of 90.98%.
View uniQure's earnings history.

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 20.3% and is now trading at $37.87.
View which stocks have been most impacted by COVID-19.

12 equities research analysts have issued twelve-month price targets for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they expect uniQure's stock price to reach $59.95 in the next year. This suggests a possible upside of 58.3% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Some companies that are related to uniQure include Legend Biotech (LEGN), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), HUTCHMED (HCM), I-Mab (IMAB), Allakos (ALLK), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Arvinas (ARVN), TG Therapeutics (TGTX), Cerevel Therapeutics (CERE), Schrödinger (SDGR) and Hypera (HYPMY).
View all of QURE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (9.58%), Federated Hermes Inc. (7.25%), Invesco Ltd. (6.73%), Point72 Asset Management L.P. (4.07%), Price T Rowe Associates Inc. MD (3.93%) and State Street Corp (3.21%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure.

QURE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Invesco Ltd., Price T Rowe Associates Inc. MD, Maven Securities LTD, Rafferty Asset Management LLC, Federated Hermes Inc., and FMR LLC. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

QURE stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Credit Suisse AG, Marshall Wace North America L.P., Sphera Funds Management LTD., Susquehanna International Group LLP, Antara Capital LP, Tekla Capital Management LLC, and Marshall Wace LLP.
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $37.87.

uniQure has a market capitalization of $1.74 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125,020,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

uniQure employs 332 workers across the globe.

The official website for uniQure is www.uniqure.com.

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000 or via email at [email protected].